{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:05:51Z","timestamp":1787702751101,"version":"build-2784847793"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11739-026-04274-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:58:51Z","timestamp":1770299931000},"page":"1185-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual targeted therapy with biologic agents and small molecules in refractory inflammatory arthritis: clinical outcomes and safety profile"],"prefix":"10.1007","volume":"21","author":[{"given":"Valeria","family":"Caggiano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sbalchiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"4274_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40265-024-02059-8","volume":"84","author":"EG Favalli","year":"2024","unstructured":"Favalli EG, Maioli G, Caporali R (2024) Biologics or Janus kinase inhibitors in rheumatoid arthritis patients who are insufficient responders to conventional anti-rheumatic drugs. Drugs 84:877\u2013894","journal-title":"Drugs"},{"key":"4274_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103819","volume":"24","author":"SG Tsiogkas","year":"2025","unstructured":"Tsiogkas SG, Gkouvi A, Kontouli KM, Simopoulou T, Grammatikopoulou MG, Bogdanos DP (2025) Janus kinase inhibitors for psoriatic arthritis: evidence from a systematic review and network meta-analysis. Autoimmun Rev 24:103819","journal-title":"Autoimmun Rev"},{"key":"4274_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82:19\u201334","journal-title":"Ann Rheum Dis"},{"key":"4274_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074329","volume":"13","author":"JW Chen","year":"2022","unstructured":"Chen JW, Zhang WS, Lin CS, Xu Q (2022) Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis. Front Immunol 13:1074329","journal-title":"Front Immunol"},{"key":"4274_CR5","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1136\/ard-2024-225800","volume":"83","author":"MG Hren","year":"2024","unstructured":"Hren MG, Khattri S (2024) Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series. Ann Rheum Dis 83:1392\u20131393","journal-title":"Ann Rheum Dis"},{"key":"4274_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020222","volume":"15","author":"G Altieri","year":"2025","unstructured":"Altieri G, Zilli A, Parigi TL, Allocca M, Furfaro F, Fiorino G et al (2025) Dual therapy in inflammatory bowel disease. Biomolecules 15:222","journal-title":"Biomolecules"},{"key":"4274_CR7","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3748\/wjg.v30.i15.2068","volume":"30","author":"JK Triantafillidis","year":"2024","unstructured":"Triantafillidis JK, Zografos CG, Konstadoulakis MM, Papalois AE (2024) Combination treatment of inflammatory bowel disease: present status and future perspectives. World J Gastroenterol 30:2068\u20132080","journal-title":"World J Gastroenterol"},{"key":"4274_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40272-023-00579-6","volume":"25","author":"A Yerushalmy-Feler","year":"2023","unstructured":"Yerushalmy-Feler A, Brauner C, Cohen S (2023) Dual-targeted therapy in pediatric inflammatory bowel disease: a comprehensive review. Paediatr Drugs 25:489\u2013498","journal-title":"Paediatr Drugs"},{"key":"4274_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ajd.13743","volume":"63","author":"A Arasu","year":"2022","unstructured":"Arasu A, Sharma N, Yazdabadi A, Sladden M (2022) Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease. Australas J Dermatol 63:110\u2013111","journal-title":"Australas J Dermatol"},{"key":"4274_CR10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00403-025-04196-w","volume":"317","author":"IC Silva","year":"2025","unstructured":"Silva IC, Daher R, Khattri S (2025) Combined use of Omalizumab and dupilumab: safety and efficacy data from a large academic center. Arch Dermatol Res 317:674","journal-title":"Arch Dermatol Res"},{"key":"4274_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jaad.2024.03.007","volume":"91","author":"MG Hren","year":"2024","unstructured":"Hren MG, Guenin S, Khattri S (2024) Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease. J Am Acad Dermatol 91:138\u2013140","journal-title":"J Am Acad Dermatol"},{"key":"4274_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1283251","volume":"14","author":"C Valero-Mart\u00ednez","year":"2023","unstructured":"Valero-Mart\u00ednez C, Urgelles JF, Sall\u00e9s M, Joven-Ib\u00e1\u00f1ez BE, de Juanes A, Ram\u00edrez J et al (2023) Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain. Front Immunol 14:1283251","journal-title":"Front Immunol"},{"key":"4274_CR13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","volume":"77","author":"R Aymon","year":"2025","unstructured":"Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D et al (2025) Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries. Arthritis Rheumatol 77:1194\u20131204","journal-title":"Arthritis Rheumatol"},{"key":"4274_CR14","volume":"17","author":"M Isa","year":"2025","unstructured":"Isa M, Ramos MRR, Kamal S (2025) Infection risk in biological disease-modifying anti-rheumatic drugs. Cureus 17:e80634","journal-title":"Cureus"},{"key":"4274_CR15","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","volume":"20","author":"W Ahmed","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ et al (2022) Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 20:e361\u2013e379","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4274_CR16","volume":"15","author":"AM Wodeyar","year":"2023","unstructured":"Wodeyar AM, Pansuriya N, Saeed S, Lakhani A, Sartaj S, Keerthi NSJ et al (2023) Upadacitinib in Crohn\u2019s disease: a comprehensive systematic review of efficacy and safety. Cureus 15:e50657","journal-title":"Cureus"},{"key":"4274_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02733","volume":"10","author":"A Watad","year":"2019","unstructured":"Watad A, Bragazzi NL, Adawi M, Shoenfeld Y, Comaneshter D, Cohen AD et al (2019) FMF is associated with a wide spectrum of MHC class I- and allied SpA disorders but not with classical MHC class II-associated autoimmune disease: insights from a large cohort study. Front Immunol 10:2733","journal-title":"Front Immunol"},{"key":"4274_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/rheumatology\/keaa378","volume":"60","author":"H Babaoglu","year":"2021","unstructured":"Babaoglu H, Armagan B, Bodakci E, Satis H, Atas N, Sari A et al (2021) Predictors of persistent inflammation in familial Mediterranean fever and association with damage. Rheumatology 60:333\u2013339","journal-title":"Rheumatology"},{"key":"4274_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae057","volume":"7","author":"S Bhaskar","year":"2024","unstructured":"Bhaskar S, Makovich Z, Mhaskar R, Coughlin E, Seminerio-Diehl J (2024) Exploring dual-targeted therapy in the management of moderate to severe inflammatory bowel disease: a retrospective study. Crohn\u2019s Colitis 360 7:otae057","journal-title":"Crohn\u2019s Colitis 360"},{"key":"4274_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaf161","volume":"19","author":"JP Gisbert","year":"2025","unstructured":"Gisbert JP, Chaparro M (2025) Combination therapy with biologics and\/or small molecules in inflammatory bowel disease: a comprehensive review. J Crohns Colitis 19:jjaf161","journal-title":"J Crohns Colitis"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04274-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04274-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:07:25Z","timestamp":1781262445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04274-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4274"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04274-5","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of Azienda Ospedaliero-Universitaria Senese, Siena, Italy (Ref. N. 14951; NCT05200715) approved the study, which was performed according to the Good Clinical Practice guidelines and the latest Declaration of Helsinki. Written informed consents for involved patients were collected. Clinical data are kept in accordance with the EU General Data Protection Regulations (GDPR), or other counterparts, on the processing of personal data and the protection of privacy (2016\/679\/EU).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement and Informed consent"}}]}}